CSBio CSBio

X
[{"orgOrder":0,"company":"HTL Biotechnology","sponsor":"Eirion Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eirion Therapeutics Announces Strategic Agreement for HTL Biotechnology to Become Eirion's Exclusive Botulinum API Manufacturer","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Large molecule","productStatus":"Approved","date":"September 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"HTL Biotechnology"},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New, Late-Breaking Data At EADV Highlights Emerging Clinical Profile of Amlitelimab (formerly KY1005) In Adults with Inadequately Controlled Moderate-To-Severe Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Sanofi"},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$4.3 million","upfrontCash":"Undisclosed","newsHeadline":"Inventiva Receives a \u20ac4 Million Milestone Payment from AbbVie for Cedirogant Phase IIb Initiation","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Inventiva Pharma"},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Inventiva Provides An Update On The Development Of Cedirogant By AbbVie","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Inventiva Pharma"},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Topline Phase 2B Data in Atopic Dermatitis Support Amlitelimab as A Potential First and Best-in-Class Novel Investigational Anti-Ox40-Ligand Monoclonal Antibody","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Large molecule","productStatus":"Approved","date":"June 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Sanofi"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            SAR445229 (amlitelimab) is a fully human non-depleting monoclonal antibody that binds to OX40-Ligand, potential to be a first-in-class treatment for a range of immune-mediated diseases and inflammatory disorders, including moderate-to-severe atopic dermatitis and asthma.

            Lead Product(s): Amlitelimab

            Therapeutic Area: Dermatology Product Name: SAR445229

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 27, 2023

            Sanofi Company Banner

            TMF Summit 2024

            Not Confirmed

            envelop Contact Supplier

            Details:

            In study, amlitelimab showed improvements in symptoms of moderate-to-severe atopic dermatitis with well-tolerated safety profile in adults whose disease can not be controlled with topical medications or for whom topical medications are not a recommended treatment approach.

            Lead Product(s): Amlitelimab

            Therapeutic Area: Dermatology Product Name: SAR445229

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 30, 2021

            Sanofi Company Banner

            TMF Summit 2024

            Not Confirmed

            envelop Contact Supplier

            Details:

            As part of the agreement, HTL will validate and operate botulinum manufacturing facility in US. Botulinum is the active ingredient in Eirion's lead product candidate ET-01, a topical neuromodulator being developed for Crow's Feet wrinkles and primary axillary hyperhidrosis.

            Lead Product(s): Botulinum toxin type A

            Therapeutic Area: Dermatology Product Name: ET-01

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Eirion Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement September 08, 2021

            Details:

            Cedirogant (ABBV-157) is an orally available retinoic acid-related orphan receptor gamma (RORγ) inverse-agonist, small molecule for the treatment of chronic plaque psoriasis.

            Lead Product(s): Cedirogant

            Therapeutic Area: Dermatology Product Name: ABBV-157

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: AbbVie Inc

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Termination October 31, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            It follows the inclusion of the first patient with psoriasis in the ongoing Phase IIb clinical trial with cedirogant (ABBV-157), an oral RORγ inverse agonist jointly discovered by Inventiva and AbbVie for the treatment of autoimmune diseases.

            Lead Product(s): Cedirogant

            Therapeutic Area: Dermatology Product Name: ABBV-157

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: AbbVie Inc

            Deal Size: $4.3 million Upfront Cash: Undisclosed

            Deal Type: Collaboration January 31, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY